Related Experiment Videos
Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future
W A Breeman1, M de Jong, D J Kwekkeboom
1Department of Nuclear Medicine, Erasmus Medical Centre Rotterdam, The Netherlands. breeman@nuge.azr.nl
Abstract:
In vivo somatostatin receptor-mediated scintigraphy has proven to be a valuable method for the visualisation of neuroendocrine tumours and their metastases. A new application is the use of radiolabelled analogues for somatostatin receptor-mediated therapy. This paper presents a review on the basic science, historical background and current knowledge of somatostatin receptor subtypes and their expression in neuroendocrine tumours. New somatostatin analogues, new chelators, "new" radionuclides and combinations thereof are also discussed. Due attention is given to limitations and future perspectives of somatostatin receptor-mediated imaging and therapy.
Insights
Somatostatin receptor imaging and therapy are valuable for neuroendocrine tumors. This review covers receptor subtypes, expression in tumors, and advances in radiolabeled somatostatin analogues for diagnosis and treatment.
Area of Science:
- Nuclear medicine
- Oncology
- Radiopharmaceutical science
Background:
- Somatostatin receptor scintigraphy is established for visualizing neuroendocrine tumors (NETs) and metastases.
- Radiolabeled somatostatin analogues offer a new avenue for receptor-mediated therapy in NETs.
Purpose of the Study:
- To review the basic science and current knowledge of somatostatin receptor subtypes and their expression in NETs.
- To discuss novel somatostatin analogues, chelators, and radionuclides for imaging and therapy.
- To explore limitations and future perspectives in somatostatin receptor-mediated applications.
Main Methods:
- Literature review of basic science, historical background, and current research.
- Discussion of somatostatin receptor subtypes and their role in NETs.
- Analysis of new developments in radiolabeled somatostatin analogues and radionuclides.
Main Results:
- Somatostatin receptor-mediated imaging is a key diagnostic tool for NETs.
- Emerging radiolabeled analogues show promise for targeted somatostatin receptor-mediated therapy.
- Advancements in analogues, chelators, and radionuclides are expanding therapeutic options.
Conclusions:
- Somatostatin receptor-mediated approaches are crucial for both diagnosing and treating neuroendocrine tumors.
- Continued research into novel analogues and radionuclides will further enhance imaging and therapeutic efficacy.
- Addressing current limitations is essential for optimizing future clinical applications.